All In Biotech

Drug Trial Radar · NCT07642505

L-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction

L-Citrulline Versus Tadalafil Versus Combination Therapy in Mild to Moderate Erectile Dysfunction: A Prospective Randomized Trial

Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 133 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

133

Planned (sponsor's estimate)

Start

Jun 8, 2026

Primary completion

Nov 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Beni-Suef UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 30 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Erectile dysfunction is a common male sexual health problem that may affect quality of life and sexual relationships. Tadalafil 5 mg once daily is an established oral treatment for erectile dysfunction. L-citrulline is an oral nitric oxide pathway supplement that may improve erectile function by increasing L-arginine availability. This randomized trial will compare three oral treatment regimens in men with mild to moderate erectile dysfunction: L-citrulline 1500 mg/day, tadalafil 5 mg/day, and the combination of L-citrulline 1500 mg/day plus tadalafil 5 mg/day. Participants will receive treatment for 12 weeks and will be followed at baseline, week 4, week 8, and week 12. The primary outcome will be the change in the International Index of Erectile Function-Erectile Function domain score from baseline to 12 weeks. Secondary outcomes will include changes in IIEF-5/SHIM score, Erection Hardness Score, SEP diary outcomes, treatment adherence, adverse events, and treatment discontinuation.

Conditions

  • Erectile Dysfunction

Interventions

  • L-CitrullineDrug

    Oral L-citrulline 1500 mg/day administered for 12 weeks as an active oral nitric oxide pathway supplement for men with mild to moderate erectile dysfunction.

  • TadalafilDrug

    Oral tadalafil 5 mg once daily administered for 12 weeks as active phosphodiesterase type 5 inhibitor therapy for men with mild to moderate erectile dysfunction.

  • L-Citrulline PlaceboDrug

    Oral placebo preparation matching L-citrulline, administered for 12 weeks as part of the double-dummy design

  • Tadalafil PlaceboDrug

    Oral placebo preparation matching tadalafil, administered for 12 weeks as part of the double-dummy study design.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in International Index of Erectile Function-Erectile Function Domain ScoreTime frame: Baseline to 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Urology- Beni-Suef University Hospitals

    Banī Suwayf, Beni Suweif Governorate, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.